Skip to main content
Premium Trial:

Request an Annual Quote

A New Vector

Amit Nathwani at the University College London Cancer Institute and his colleagues tested a gene therapy approach for hemophilia B using an adenovirus-associated virus vector — one that's different from previously used adenovirus vectors — to deliver a corrected coagulation factor IX, or FIX, gene. As they report in the New England Journal of Medicine, Nathwani and his team performed a combined phase 1 and 2 clinical trial of their approach on six male patients with hemophilia B. "We have found that a single peripheral-vein infusion of our scAAV2/8-LP1-hFIXco vector consistently leads to long-term expression of the FIX transgene at therapeutic levels, without acute or long-lasting toxicity in patients with severe hemophilia B," the authors write.

"The idea of treating hemophilia with gene therapy has been around for 25 years, but the problem was how to do it right," says Ronald Crystal from Weill Cornell Medical College in The Wall Street Journal. "This is an important breakthrough because it is the first success in one of the plasma deficiency disorders and shows gene therapy is feasible."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.